We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
52 hedge funds and large institutions have $360M invested in Corvus Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
44% more capital invested
Capital invested by funds: $250M → $360M (+$110M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.79% less ownership
Funds ownership: 83.62% → 82.82% (-0.79%)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
2% less funds holding
Funds holding: 53 → 52 (-1)
Holders
52
Holders Change
-1
Holders Change %
-1.89%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
10
Increased
16
Reduced
17
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.86M |
| 3 |
BlackRock
New York
|
+$2.79M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.05M |
| 5 |
Renaissance Technologies
New York
|
+$905K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.81M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.84M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$1.49M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$643K |
| 5 |
Millennium Management
New York
|
-$564K |
